The document discusses declining U.S. competitiveness in biomedical research compared to other countries. It notes that U.S. global leadership in this area grew from scientific research in WWII but that federal funding for biomedical research has not kept pace with inflation. As a result, other countries like China are increasing their funding and output of biomedical research, threatening U.S. leadership. The document recommends that Congress increase and sustain funding for agencies like NIH to at least 0.25% of GDP and support additional policies to maintain U.S. competitiveness in this important industry.
In this SlideShare, we'll provide an overview of the biggest vaccination campaign in history. Since governments around the world began vaccinating their populations in December 2020, there is a striking gap between higher-income countries with the rest of the world. To date (10th June 2021), more than 2.25 billion doses have been administered, yet low-income countries are still far behind, receiving only 0.3% of doses administered.
The annual 2013 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
The COVID-19 vaccine race is progressing rapidly, with a handful of candidates already entering Phase 3 clinical trials in Q3 2020. Deals are being struck between developed nations and the top vaccine developers to secure doses even before FDA approval. Coalitions & alliances are also being set up to ensure vaccine access for lower-income countries.
These slides highlight the approved & widely used therapeutics for treating COVID-19 patients (end Q1 2021). At the time of writing, there are 5 therapeutics that have been granted Emergency Use Authorization by the US FDA, mostly being antivirals and monoclonal antibodies (mAbs). The use of corticosteroids and cytokine inhibitors are also showing promise in their ability to reduce case fatalities, progression as well as hospitalization time.
In this section of the coronavirus pandemic series, we discuss the current capacity of local healthcare systems and the need for effective treatment options as well as the pathogenesis of the coronavirus. Current treatment options include RNA, monoclonal antibodies (mAb), antibodies, convalescent plasma, and others. Critical stage implications such as cytokine storm and the need for immunomodulatory agents would also be discussed. Therapeutic pathways would are also compared.
In this SlideShare, we'll provide an overview of the biggest vaccination campaign in history. Since governments around the world began vaccinating their populations in December 2020, there is a striking gap between higher-income countries with the rest of the world. To date (10th June 2021), more than 2.25 billion doses have been administered, yet low-income countries are still far behind, receiving only 0.3% of doses administered.
The annual 2013 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.
In this SlideShare, we're covering an overview on RNA technologies and recent applications in the field of life sciences. RNA is the pivotal ‘molecule of life’, involved in almost all aspects of cell biology. Recent successes in mRNA-based vaccines indicate just one of the near-infinite possibilities that RNA technology can offer in life sciences.
The COVID-19 vaccine race is progressing rapidly, with a handful of candidates already entering Phase 3 clinical trials in Q3 2020. Deals are being struck between developed nations and the top vaccine developers to secure doses even before FDA approval. Coalitions & alliances are also being set up to ensure vaccine access for lower-income countries.
These slides highlight the approved & widely used therapeutics for treating COVID-19 patients (end Q1 2021). At the time of writing, there are 5 therapeutics that have been granted Emergency Use Authorization by the US FDA, mostly being antivirals and monoclonal antibodies (mAbs). The use of corticosteroids and cytokine inhibitors are also showing promise in their ability to reduce case fatalities, progression as well as hospitalization time.
In this section of the coronavirus pandemic series, we discuss the current capacity of local healthcare systems and the need for effective treatment options as well as the pathogenesis of the coronavirus. Current treatment options include RNA, monoclonal antibodies (mAb), antibodies, convalescent plasma, and others. Critical stage implications such as cytokine storm and the need for immunomodulatory agents would also be discussed. Therapeutic pathways would are also compared.
Slides from the presentation at IDAMO 2016, Rostock. May 2016.
Most scientific discoveries rely on previous or other findings. A lack of transparency and openness led to what many consider the "reproducibility crisis" in systems biology and systems medicine. The crisis arose from missing standards and inappropriate support of
standards in software tools. As a consequence, numerous results in low-and high-profile publications cannot be reproduced.
In my presentation, I summarise key challenges of reproducibility in systems biology and systems medicine, and I demonstrate available solutions to the related problems.
A National Network of Biomedical Research ExpertiseManinder Kahlon
Overview of status on a Clinical & Translational Science Award Consortium project co-lead by UCSF and Harvard to link biomedical experts across the country.
My presentation on Healthcare Information Exchange technical infrastructure given as a skills building session at the eHealth Conference in Kenya (http://www.e-healthconference.or.ke/)
Working in Global HealthChapter 18Chapter 18 Working irosacrosdale
Working in Global Health
Chapter 18
Chapter 18: Working in Global Health
1
Positions in Global Health
Universities
NGOs
Social entrepreneurships
Bilateral and multilateral aid organizations
Consulting
Global health is a growing field and there are many opportunities to work in it.
2
When considering a job in Global health
Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
If you are considering a job in global health, you should: Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
3
Other valuable points
Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
Other things to consider are: Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
4
Resources for careers
DEVEX http://globalhealth.org/
The Global Health Council http://globalhealth.org/
Global Health Hub www.globalhealthhub.org
International Jobs Center http://www.internationaljobs.org/
Idealist www.idealist.org
U.S Government
USAID https://www.usaid.gov/
CDC http://www.cdc.gov/
Here are a few resources to consider when looking for a career in global health.
5
Personal Quote
“Working in global health has been my dream as long as I can remember. And just imagine how reality could be better than a dream- and that’s exactly how I feel working in this field. It’s the most fulfilling career that I could ever imagine.”
Dr. Tara Rava Zolnikov
Assistant Professor
National University
Water project in Narok, Kenya
HIV/AIDS project in Busia, Kenya
Access to water research in Kitui, Kenya
Science, Technology, and Global Health
Chapter 17
1
Chapter 17: Science, Technology, and Global Health
The Need for New Products
Characteristics of new technologies must reflect the following:
Most important target groups are poor people.
Quality of care and injection safety is often low.
Many low- and middle-income countries have poorly organized health systems.
Science and technology ...
Slides from the presentation at IDAMO 2016, Rostock. May 2016.
Most scientific discoveries rely on previous or other findings. A lack of transparency and openness led to what many consider the "reproducibility crisis" in systems biology and systems medicine. The crisis arose from missing standards and inappropriate support of
standards in software tools. As a consequence, numerous results in low-and high-profile publications cannot be reproduced.
In my presentation, I summarise key challenges of reproducibility in systems biology and systems medicine, and I demonstrate available solutions to the related problems.
A National Network of Biomedical Research ExpertiseManinder Kahlon
Overview of status on a Clinical & Translational Science Award Consortium project co-lead by UCSF and Harvard to link biomedical experts across the country.
My presentation on Healthcare Information Exchange technical infrastructure given as a skills building session at the eHealth Conference in Kenya (http://www.e-healthconference.or.ke/)
Working in Global HealthChapter 18Chapter 18 Working irosacrosdale
Working in Global Health
Chapter 18
Chapter 18: Working in Global Health
1
Positions in Global Health
Universities
NGOs
Social entrepreneurships
Bilateral and multilateral aid organizations
Consulting
Global health is a growing field and there are many opportunities to work in it.
2
When considering a job in Global health
Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
If you are considering a job in global health, you should: Understand the skills, knowledge, and experience this type of career would entail and how you might fill gaps you have in terms of the required background for a position.
May require a good understanding of economic development.
Should appreciate cultures.
Have the ability to write and speak well.
Be willing to live and work in low and middle income countries.
3
Other valuable points
Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
Other things to consider are: Get your degree in an area related to the one in which you want to work.
Build on that area through internships, fellowships, and other opportunities to live and work abroad.
Consider a graduate program to build in your studies and experiences.
Work with mentors who work directly in the field.
4
Resources for careers
DEVEX http://globalhealth.org/
The Global Health Council http://globalhealth.org/
Global Health Hub www.globalhealthhub.org
International Jobs Center http://www.internationaljobs.org/
Idealist www.idealist.org
U.S Government
USAID https://www.usaid.gov/
CDC http://www.cdc.gov/
Here are a few resources to consider when looking for a career in global health.
5
Personal Quote
“Working in global health has been my dream as long as I can remember. And just imagine how reality could be better than a dream- and that’s exactly how I feel working in this field. It’s the most fulfilling career that I could ever imagine.”
Dr. Tara Rava Zolnikov
Assistant Professor
National University
Water project in Narok, Kenya
HIV/AIDS project in Busia, Kenya
Access to water research in Kitui, Kenya
Science, Technology, and Global Health
Chapter 17
1
Chapter 17: Science, Technology, and Global Health
The Need for New Products
Characteristics of new technologies must reflect the following:
Most important target groups are poor people.
Quality of care and injection safety is often low.
Many low- and middle-income countries have poorly organized health systems.
Science and technology ...
2016 Overview of significant trends in the life sciences (Biotechnology, Pharmaceutical, Device and Diagnostics) industry with Regenerative Medicine feature articles.
2014 Profile: Biopharmaceutical Research IndustryPhRMA
Biopharmaceutical science is a complex, collaborative, resource-intensive enterprise. It requires a highly skilled workforce, sustained investment, and long-term vision. Critical to its success are policies and regulations that foster innovation and broad access to new medicines. By working together—on the science, the research and the policies—we
can help ensure that medicines live up to patients’ hope for new solutions to our greatest health care challenges.
Future of the Global Pharmaceutical IndustryTim Opler
Key points in presentation from Torreya Partners.
Despite concerns regarding research productivity and pricing pressure, Torreya is optimistic about the pharma sector. There is huge growth ahead driven by expanding global wealth.
The global pharma sector is going to at least triple in scale between now and 2060.
The pharmaceutical sector is 30% larger than shown by prior data.
New technologies in manufacture, biologics, nucleic acids and implantables will dramatically alter the pharma sector.
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Afternoon Keynote Presentation
Dr. Michael S. Perry, Venture Partner, Bay City Capital; President and Chief Medical Officer, Poniard Pharmaceuticals (US)
MaRS Innovation Summit
October 28, 2010
The problem is that we have a health industry that is not concerned with food…
…and a food industry that is not concerned with health.
For further information on how to invest please contact:
Andrew Haythorpe
Founder, Managing Director
Mobile: +61407 737 973
Email: a@bettercells.com
Skype: andrewhaythorpe
The 2019 edition of the Global Innovation Index (GII) focuses
on the theme Creating Healthy Lives—The Future of Medical
Innovation. In the years to come, medical innovations such
as artificial intelligence (AI), genomics, and mobile health
applications will transform the delivery of healthcare in both
developed and emerging nations.
The key questions addressed in this edition of the GII include:
• What is the potential impact of medical innovation on
society and economic growth, and what obstacles must
be overcome to reach that potential?
• How is the global landscape for research and development
(R&D) and medical innovation changing?
• What health challenges do future innovations need to address
and what types of breakthroughs are on the horizon?
• What are the main opportunities and obstacles to future
medical innovation and what role might new policies play?
ITIF president Rob Atkinson delivers the keynote address at the STGlobal Conference. STGlobal Consortium is an international, interdisciplinary organization of leading graduate programs in science and technology policy (STP) and science and technology studies (STS). Its mission is to inspire and challenge graduate students to contribute to the forefront of research on science and technology policy and social issues, and to foster mutual understanding in the S&T community.
ITIF Senior Analyst Stephen Ezell presented on the future of advanced manufacturing at the AAAS annual conference. His presentation argued for the correct policies to support a robust advanced manufacturing climate in the United States.
Taking the whole picture into account, this report finds that the United States has made rapid progress in broadband deployment, performance, and price, as well as adoption when measured as computer-owning households who subscribe to broadband. Considering the high cost of operating and upgrading broadband networks in a largely suburban nation, the prices Americans pay for broadband services are reasonable and the performance of our networks is better than in all but a handful of nations that have densely populated urban areas and have used government subsidies to leap-frog several generations of technology ahead of where the market would go on its own in response to changing consumer demands. All in all, the state of American broadband is good and getting better, but there is still room for improvement in selected areas.
Stephen Ezell presented ITIF's work on competitiveness, innovation, and productivity as well as evidence from our various reports on countries innovation rankings at the 2012 EPISIS Conference.
In the last decade, manufacturing job growth in the United States has been slower than in any other developed nation. Rob Atkinson calls for a national industrial policy that fosters innovation through tax incentives, workforce development and technology investments. Further, many economists maintain a market-driven approach to policy that has dominated decision-making in Washington. More government and private industry partnerships are needed to re-establish the United States as a global manufacturing leader.
On September 19, 2011, ITIF Senior Analyst Daniel Castro spoke on a panel at the Global IP Academy’s “Copyright in the Digital Age” program sponsored by the United States Copyright Office and the Patent and Trademark Office (USPTO). His panel was entitled “Copyright Technology 101” and he discussed the various controls that can be used to protect intellectual property in different parts of the Internet ecosystem. The program was held at the USPTO in Alexandria, Virginia and included approximately 50 foreign government officials working on copyright issues.
Senior Fellow Val Giddings, as part of "Innovation Day" 2011, presents on the importance of chemistry in evolving sustainable agricultural practices. He argues both Green Revolution Solutions (internal involving topical applications of pesticides/herbicides, external apps of fertilizers) and Doubly Green Revolution Solutions (building on GR but adding solutions from work with internal chemistry) are essential and indispensible to feeding a world population of billions.
In a featured presentation at the ATSE Forum, Rob Atkinson stresses the relationship between innovation and productivity. All nations need an innovation-productivity strategy because addressing complex and systemic challenges–such as achieving affordable health care, combating global climate change, achieving sustainable energy production, deploying digital infrastructure, etc.–requires coordinated strategies leveraging the resources of firms, government, academia. And, in contrast to what the conventional neo-classical economic doctrine holds, markets alone will produce societally sub-optimal levels of innovation.
At the ACT-IAC 2011 Executive Leadership Conference, ITIF president Rob Atkinson presented on the importance of innovation in IT and government leadership in IT practices. This presentation highlights the innovator’s challenge of exploiting and exploring industry facets simultaneously.
The Great Recession officially ended more than two years ago but the recovery is barely perceptible and anxious policymakers are running out of options. Washington cannot seem to agree on what caused the Recession in the first place or how to create robust job growth. One camp argues for revving up consumer demand through fiscal and monetary policy. The other says the financial system got out of control and we just have to wait for our books to get back into balance.
Remarkably, neither of the dominant schools of thought focuses on the principal cause of the Great Recession and our current anemic jobs recovery- the collapse of U.S. manufacturing and innovation-based competitiveness over the last generation. Faulty diagnosis leads to ineffective cures. It's time for a new approach grounded in a new diagnosis.
"Three pillars for ITS Development: National Vision, Investment, Strong Government Leadership" focuses on the importance of ITS for developing economies.
More from Information Technology and Innovation Foundation (20)
Leadership in Decline: Assessing U.S. International Competitiveness in Biomedical Research
1. May 17, 2012
Leadership in Decline: Assessing
U.S. International
Competitiveness
in Biomedical Research
Presenters:
Dr. Robert D. Atkinson, President, ITIF
Representative Kevin Yoder, (Kansas-3)
Dr. Francis Collins, Director, National Institutes of Health
Scott Bruder, SVP/Chief Science & Technology Officer, BD
Landon S. King, Vice Dean for Research, Johns Hopkins Medicine
2. U.S. Competitiveness in Biomedical Research
U.S. global leadership grew from the value of scientific
research proven in World War II.
2
3. U.S. Competitiveness in Biomedical Research
U.S. global leadership grew from the value of scientific
research proven in World War II.
Federally funded biomedical research has been a key
input both to new drugs and biologics and entirely
new companies.
3
5. U.S. Competitiveness in Biomedical Research
U.S. global leadership grew from the value of scientific
research proven in World War II.
Federally funded biomedical research has been a key input
to both new drugs and biologics and entirely new
companies.
Major economic benefits & consistently high returns
on federal research investment (societal ROI greater
than 30% per yr).
U.S. life sciences industry today = 7 million jobs &
$69B in GDP.
5
6. U.S. Leadership Today is Under Threat
1. Life science research funding has not kept pace with
inflation, much less Congress’ pledge to double
NIH funding.
6
9. U.S. Leadership Today is Under Threat
1. Funding has not kept pace with inflation, much less
Congress’ pledge to double.
2. Competitors ramping up efforts with intent to stake
their own claims on global leadership:
China spending $308B over next 5y (4x U.S. as
share GDP); leads world in DNA sequencing
capacity.
Germany, India, Singapore, Sweden, UK, etc. all
increasing funding and honing policies to gain
global market share.
9
14. What Is To Be Done?
1. We cannot get out of our current budget dilemma
by cutting investment.
2. Growth driven by investment is critical to good
jobs, GDP growth and overall federal tax
revenues. As such Congress should distinguish
between investment and consumption
expenditures.
3. Biomedical research is not a luxury; it is an
essential keystone for economic growth (and
human health improvement) in the 21st century.
14
16. Policy Recommendations
1. Congress should target sustained funding for NIH of
at least 0.25% of GDP.
2. Life sciences funding in other agencies (e.g.,
DOE, USDA) should be increased
commensurately.
16
17. Policy Recommendations
1. Congress should target sustained funding for NIH of
at least 0.25% of GDP.
2. Life sciences funding in other agencies (e.g., DOE,
USDA) should be increased commensurately.
3. Funding increases should be steady year over
year.
17
18. Policy Recommendations
1. Congress should target sustained funding for NIH of
at least 0.25% of GDP.
2. Life sciences funding in other agencies (e.g., DOE,
USDA) should be increased commensurately.
3. Funding increases should be steady year over year.
4. Supportive policies are also critical (e.g., tax
incentives; FDA reform; high-skill immigration;
and targeted trade enforcement against foreign
life sciences’ mercantilist practices).
18
Benefits from scientific research in WWII included antibiotics, saving tens of thousands of lives (also radar, fission…).Policy to fund science research in general, and biomedical in particular, really took off in 1948.Major funding surge with War on Cancer (1971; Nixon).
NIH Funding Trajectory:Steady increases since 1948;Major increase with War on Cancer (1971);Congress pledged to double funding ;Pledge met by 2002/3but not sustained; steady declines since 2003 except for ARRA blip;7.8% cuts planned under sequestration ($2.4B).
Average success rate of first time grant applicants has steadily declined from 58% (1963) to less than 20% (2011); average age of first time recipients has increased from 34 (1970) to 42 (2005).Huge backlog of good ideas and promising opportunities unfunded; stunted careers and enormous opportunity costs.
China spending twice as much in constant dollars, 4x as much as share of GDP;
US funding essentially flat while every other country considered is increasing support.
Caveat – different countries have varying thresholds for patentability. China’s threshold is lower than US, so the significance of the apparent shift may be somewhat exaggerated, but the curves of the slopes are valid nevertheless…
0.25% of US GDP ~ 40 Billion/year.
0.25% of US GDP ~ 40 Billion/yearSupportive policies are essential to maximizing ROI; without good policies investments will be inefficient. We need funding increases but also tax/regulatory/immigration reforms.
0.25% of US GDP ~ 40 Billion/yearSupportive policies are essential to maximizing ROI; without good policies investments will be inefficient. We need funding increases but also tax/regulatory/immigration reforms.
0.25% of US GDP ~ 40 Billion/yearSupportive policies are essential to maximizing ROI; without good policies investments will be inefficient. We need funding increases but also tax/regulatory/immigration reforms.